|
業務類別
|
Biotechnology |
|
業務概覽
|
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targetingtumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States. |
| 公司地址
| 11055 Flintkote Avenue, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 952-7570 |
| 傳真號碼
| +1 858 952-7571 |
| 公司網頁
| https://www.cardiffoncology.com |
| 員工數量
| 31 |
| Dr. Tod Smeal, PhD |
Chief Scientific Officer |
-- |
29/04/2025 |
| Dr. Roger Sidhu |
Chief Medical Officer |
-- |
17/06/2025 |
| Dr. Mani Mohindru, PhD |
Director and Interim Chief Executive Officer |
-- |
27/01/2026 |
| Ms. Brigitte Lindsay |
Chief Accounting Officer |
-- |
27/01/2026 |
|
|
| Dr. James O. Armitage,M.D. |
Independent Director |
24/02/2026 |
| Dr. Gary W. Pace,PhD |
Independent Director |
24/02/2026 |
| Dr. Renee P. Tannenbaum, D.Pharm. |
Independent Director |
24/02/2026 |
| Dr. Mani Mohindru, PhD |
Director and Interim Chief Executive Officer |
27/01/2026 |
| Ms. Lale White |
Independent Director |
24/02/2026 |
| Dr. Rodney S. Markin,M.D.,PhD |
Chairman of the Board |
24/02/2026 |
|
|
|
|
